Matrix metalloprotease 9 (MMP-9) is a 92 kDa type IV collagenase and a member of the family of endopeptidases. MMP-9 is involved in the degradation of extracellular matrix components, tissue remodeling, cellular receptor stripping, and processing of various signaling molecules. In the CNS, the effects of MMP-9 are quite complex, since it exerts beneficial effects including neurogenesis, angiogenesis, myelogenesis, axonal growth, and inhibition of apoptosis, or destructive effects including apoptosis, blood-brain barrier disorder, and demyelination. Likewise, in the periphery, physiological events, as the involvement of MMP-9 in angiogenesis, for instance in wound healing, can be turned into pathological, such as in tumor metastasis, depending on the state of the organism. Alzheimer’s disease is a neurodegenerative disorder, characterized by amyloid accumulation and deposition in the brain. Amyloidogenesis, however, also occurs in diseases of the periphery, such as type II diabetes mellitus, where an analogous type of amyloid, is deposited in the pancreas. Interestingly, both diseases exhibit similar pathology and disease progression, with insulin resistance being a major common denominator. Hence, combinatorial strategies searching new or existing molecules to apply for therapeutic use for both diseases are gaining momentum. MMP-9 is extensively studied due to its association with a variety of physiological and pathological processes. Consequently, meticulous design could render MMP-9 into a potential therapeutic target for Alzheimer’s disease and type 2 diabetes mellitus; two seemingly unrelated diseases.
St JeanPL, ZhangXC, HartBK, LamlumH, WebsterMW, SteedDL, HenneyAM, FerrellRE. (1995) Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Ann Hum Genet59, 17–24.
3.
VandoorenJ, Van den SteenPE, OpdenakkerG. (2013) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev Biochem Mol Biol48, 222–272.
4.
RowsellS, HawtinP, MinshullCA, JepsonH, BrockbankSM, BarrattDG, SlaterAM, McPheatWL, WatersonD, HenneyAM, PauptitRA. (2002) Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol319, 173–181.
5.
TallantC, MarreroA, Gomis-RuthFX. (2010) Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim Biophys Acta1803, 20–28.
6.
Van den SteenPE, DuboisB, NelissenI, RuddPM, DwekRA, OpdenakkerG. (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol37, 375–536.
7.
LiL, HolscherC. (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev56, 384–402.
8.
KayedR, HeadE, ThompsonJL, McIntireTM, MiltonSC, CotmanCW, GlabeCG. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science300, 486–489.
9.
LucaS, YauWM, LeapmanR, TyckoR. (2007) Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid-state NMR. Biochemistry46, 13505–13522.
10.
LimYA, IttnerLM, LimYL, GotzJ. (2008) Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett582, 2188–2194.
11.
LorenzoA, RazzaboniB, WeirGC, YanknerBA. (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature368, 756–760.
12.
CooperGJ, WillisAC, ClarkA, TurnerRC, SimRB, ReidKB. (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A84, 8628–8632.
13.
JonesA, KulozikP, OstertagA, HerzigS. (2009) Common pathological processes and transcriptional pathways in Alzheimer’s disease and type 2 diabetes. J Alzheimers Dis16, 787–808.
14.
PeilaR, RodriguezBL, LaunerLJ, Honolulu-Asia Aging S
(2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes51, 1256–1262.
15.
LuchsingerJA, ReitzC, HonigLS, TangMX, SheaS, MayeuxR. (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology65, 545–551.
16.
AkintolaAA, van HeemstD. (2015) Insulin, aging, and the bra, Mechanisms and imlications. Front Endocrinol (Lausanne)6, 13.
17.
de la MonteSM, WandsJR (2008) Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol2, 1101–1113.
18.
FemminellaGD, BencivengaL, PetragliaL, VisaggiL, GioiaL, GriecoFV, de LuciaC, KomiciK, CorbiG, EdisonP, RengoG, FerraraN. (2017) Antidiabetic drugs in Alzheimer’s disease: Mechanisms of action and future perspectives. J Diabetes Res2017, 7420796.
19.
HuJ, Van den SteenPE, SangQX, OpdenakkerG. (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov6, 480–498.
20.
OverallCM, KleifeldO. (2006) Tumour microenvironment - opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer6, 227–239.
21.
VafadariB, SalamianA, KaczmarekL. (2016) MMP-9 in translation: From molecule to brain physiology, pathology, and therapy. J Neurochem139(Suppl 2), 91–114.
22.
BrkicM, BalusuS, LibertC, VandenbrouckeRE. (2015) Friends or foes: Matrix metalloproteinases and their multifaceted roles in neurodegenerative diseases. Mediators Inflamm2015, 620581.
GlennerGG, WongCW. (1984) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun120, 885–890.
25.
DawkinsE, SmallDH. (2014) Insights into the physiological function of the beta-amyloid precursor prote, Beyond Alzheimer’s disease. J Neurochem129, 756–769.
SakonoM, ZakoT. (2010) Amyloid oligomers: Formation and toxicity of Abeta oligomers. FEBS J277, 1348–1358.
30.
LorenzlS, AlbersDS, RelkinN, NgyuenT, HilgenbergSL, ChirichignoJ, CudkowiczME, BealMF. (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease. Neurochem Int43, 191–196.
31.
LorenzlS, BuergerK, HampelH, BealMF. (2008) Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr20, 67–76.
32.
StomrudE, BjorkqvistM, JanciauskieneS, MinthonL, HanssonO. (2010) Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer’s disease. Alzheimers Res Ther2, 20.
33.
HorstmannS, BudigL, GardnerH, KoziolJ, DeuschleM, SchillingC, WagnerS. (2010) Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer’s disease. Int Psychogeriatr22, 966–972.
34.
LimNK, VillemagneVL, SoonCP, LaughtonKM, RoweCC, McLeanCA, MastersCL, EvinG, LiQX. (2011) Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer’s disease. J Alzheimers Dis26, 779–786.
35.
HanzelCE, IulitaMF, EyjolfsdottirH, HjorthE, SchultzbergM, EriksdotterM, CuelloAC. (2014) Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer’s disease cerebrospinal fluid. J Alzheimers Dis40, 667–678.
36.
MroczkoB, GroblewskaM, ZbochM, KulczynskaA, KoperOM, SzmitkowskiM, KornhuberJ, LewczukP. (2014) Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer’s disease. J Alzheimers Dis40, 351–357.
37.
NalivaevaNN, FiskLR, BelyaevND, TurnerAJ. (2008) Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res5, 212–224.
38.
MinersJS, BaruaN, KehoePG, GillS, LoveS. (2011) Abeta-degrading enzymes: Potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol70, 944–959.
RidnourLA, DhanapalS, HoosM, WilsonJ, LeeJ, ChengRY, BrueggemannEE, HinesHB, WilcockDM, VitekMP, WinkDA, ColtonCA. (2012) Nitric oxide-mediated regulation of beta-amyloid clearance via alterations of MMP-9/TIMP-1. J Neurochem123, 736–749.
41.
BackstromJR, LimGP, CullenMJ, TokesZA. (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci16, 7910–7919.
42.
YanP, HuX, SongH, YinK, BatemanRJ, CirritoJR, XiaoQ, HsuFF, TurkJW, XuJ, HsuCY, HoltzmanDM, LeeJM. (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem281, 24566–24574.
43.
TalamagasAA, EfthimiopoulosS, TsilibaryEC, Figueiredo-PereiraME, TziniaAK. (2007) Abeta(1-40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP. Neurobiol Dis28, 304–315.
44.
FragkouliA, TziniaAK, CharalampopoulosI, GravanisA, TsilibaryEC. (2011) Matrix metalloproteinase-9 participates in NGF-induced alpha-secretase cleavage of amyloid-beta protein precursor in PC12 cells. J Alzheimers Dis24, 705–719.
FragkouliA, TsilibaryEC, TziniaAK. (2014) Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer’s 5xFAD mice. Neurobiol Dis70, 179–189.
47.
SkaperSD, FacciL, ZussoM, GiustiP. (2017) Synaptic plasticity, dementia and Alzheimer disease. CNS Neurol Disord Drug Targets16, 220–233.
48.
HuntleyGW. (2012) Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci13, 743–757.
49.
MuirEM, AdcockKH, MorgensternDA, ClaytonR, von StillfriedN, RhodesK, EllisC, FawcettJW, RogersJH. (2002) Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res100, 103–117.
50.
GottschallPE, YuX, BingB. (1995) Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res42, 335–342.
51.
UhmJH, DooleyNP, OhLY, YongVW. (1998) Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia22, 53–63.
52.
Oliveira-SilvaP, JurgilasPB, TrindadeP, Campello-CostaP, PeralesJ, SavinoW, SerfatyCA. (2007) Matrix metalloproteinase-9 is involved in the development and plasticity of retinotectal projections in rats. Neuroimmunomodulation14, 144–149.
53.
AujlaPK, HuntleyGW. (2014) Early postnatal expression and localization of matrix metalloproteinases-2 and -9 during establishment of rat hippocampal synaptic circuitry. J Comp Neurol522, 1249–1263.
54.
BarkhoBZ, MunozAE, LiX, LiL, CunninghamLA, ZhaoX. (2008) Endogenous matrix metalloproteinase (MMP)-3 and MMP-9 promote the differentiation and migration of adult neural progenitor cells in response to chemokines. Stem Cells26, 3139–3149.
55.
IngrahamCA, ParkGC, MakarenkovaHP, CrossinKL. (2011) Matrix metalloproteinase (MMP)-9 induced by Wnt signaling increases the proliferation and migration of embryonic neural stem cells at low O2 levels. J Biol Chem286, 17649–17657.
56.
Wojcik-StanaszekL, GregorA, ZalewskaT. (2011) Regulation of neurogenesis by extracellular matrix and integrins. Acta Neurobiol Exp (Wars)71, 103–112.
57.
SzklarczykA, LapinskaJ, RylskiM, McKayRD, KaczmarekL. (2002) Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci22, 920–930.
58.
GawlakM, GorkiewiczT, GorlewiczA, KonopackiFA, KaczmarekL, WilczynskiGM. (2009) High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses. Neuroscience158, 167–176.
WangXB, BozdagiO, NikitczukJS, ZhaiZW, ZhouQ, HuntleyGW. (2008) Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci U S A105, 19520–19525.
61.
TurnerPR, O’ConnorK, TateWP, AbrahamWC. (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol70, 1–32.
BourA, LittleS, DodartJC, KelcheC, MathisC. (2004) A secreted form of the beta-amyloid precursor protein (sAPP695) improves spatial recognition memory in OF1 mice. Neurobiol Learn Mem81, 27–38.
64.
AndersonJJ, HoltzG, BaskinPP, WangR, MazzarelliL, WagnerSL, MenzaghiF. (1999) Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: Correlation with spatial memory deficits. Neuroscience93, 1409–1420.
65.
LannfeltL, BasunH, WahlundLO, RoweBA, WagnerSL. (1995) Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s disease. Nat Med1, 829–832.
66.
ColciaghiF, BorroniB, PastorinoL, MarcelloE, ZimmermannM, CattabeniF, PadovaniA, Di LucaM. (2002) [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med8, 67–74.
67.
AlmkvistO, BasunH, WagnerSL, RoweBA, WahlundLO, LannfeltL. (1997) Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Arch Neurol54, 641–644.
68.
DuarteAI, MoreiraPI, OliveiraCR. (2012) Insulin in central nervous system: More than just a peripheral hormone. J Aging Res2012, 384017.
69.
WangX, YuS, GaoSJ, HuJP, WangY, LiuHX. (2014) Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer’s disease. Neuro Endocrinol Lett35, 224–229.
JimenezS, TorresM, VizueteM, Sanchez-VaroR, Sanchez-MejiasE, Trujillo-EstradaL, Carmona-CuencaI, CaballeroC, RuanoD, GutierrezA, VitoricaJ. (2011) Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem286, 18414–18425.
72.
DouJT, ChenM, DufourF, AlkonDL, ZhaoWQ. (2005) Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn Mem12, 646–655.
73.
CrowderRJ, FreemanRS. (1998) Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J Neurosci18, 2933–2943.
74.
Boura-HalfonS, ZickY. (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab296, 581–591.
75.
HooperC, KillickR, LovestoneS. (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem104, 1433–1439.
76.
MaQL, YangF, RosarioER, UbedaOJ, BeechW, GantDJ, ChenPP, HudspethB, ChenC, ZhaoY, VintersHV, FrautschySA, ColeGM. (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci29, 9078–9089.
77.
BomfimTR, Forny-GermanoL, SathlerLB, Brito-MoreiraJ, HouzelJC, DeckerH, SilvermanMA, KaziH, MeloHM, McCleanPL, HolscherC, ArnoldSE, TalbotK, KleinWL, MunozDP, FerreiraST, De FeliceFG. (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest122, 1339–1353.
78.
TalbotK, WangHY, KaziH, HanLY, BakshiKP, StuckyA, FuinoRL, KawaguchiKR, SamoyednyAJ, WilsonRS, ArvanitakisZ, SchneiderJA, WolfBA, BennettDA, TrojanowskiJQ, ArnoldSE. (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest122, 1316–1338.
MoloneyAM, GriffinRJ, TimmonsS, O’ConnorR, RavidR, O’NeillC. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging31, 224–243.
81.
KaminariA, GiannakasN, TziniaA, TsilibaryEC. (2017) Overexpression of matrix metalloproteinase-9 (MMP-9) rescues insulin-mediated impairment in the 5XFAD model of Alzheimer’s disease. Sci Rep7, 683.
82.
Candelario-JalilE, YangY, RosenbergGA. (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience158, 983–994.
BackstromJR, MillerCA, TokesZA. (1992) Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: Identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem58, 983–992.
87.
BjerkeM, ZetterbergH, EdmanA, BlennowK, WallinA, AndreassonU. (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis27, 665–676.
88.
DuitsFH, Hernandez-GuillamonM, MontanerJ, GoosJD, MontanolaA, WattjesMP, BarkhofF, ScheltensP, TeunissenCE, van der FlierWM. (2015) Matrix metalloproteinases in Alzheimer’s disease and concurrent cerebral microbleeds. J Alzheimers Dis48, 711–720.
89.
AdairJC, CharlieJ, DencoffJE, KayeJA, QuinnJF, CamicioliRM, Stetler-StevensonWG, RosenbergGA. (2004) Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke35, 159–162.
RaiS, KamatPK, NathC, ShuklaR. (2014) Glial activation and post-synaptic neurotoxicity: The key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav117, 104–117.
92.
RiesM, SastreM. (2016) Mechanisms of Abeta clearance and degradation by glial cells. Front Aging Neurosci8, 160.
93.
JantzenPT, ConnorKE, DiCarloG, WenkGL, WallaceJL, RojianiAM, CoppolaD, MorganD, GordonMN. (2002) Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci22, 2246–2254.
94.
Wyss-CorayT, LoikeJD, BrionneTC, LuE, AnankovR, YanF, SilversteinSC, HusemannJ. (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med9, 453–457.
95.
DebS, Wenjun ZhangJ, GottschallPE. (2003) Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res970, 205–213.
KahnSE, CooperME, Del PratoS. (2014) Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet383, 1068–1083.
98.
FuZ, GilbertER, LiuD. (2013) Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev9, 25–53.
OlssonM, HerringtonMK, ReidelbergerRD, PermertJ, Gebre-MedhinS, ArneloU. (2012) Food intake and meal pattern in IAPP knockout mice with and without infusion of exogenous IAPP. Scand J Gastroenterol47, 191–196.
101.
MontaneJ, CadavezL, NovialsA. (2014) Stress and the inflammatory process: A major cause of pancreatic cell death in type 2 diabetes. Diabetes Metab Syndr Obes7, 25–34.
102.
TomitaT, IwataK. (1997) Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Pathol10, 47–54.
103.
SignorelliSS, MalaponteG, LibraM, Di PinoL, CelottaG, BevelacquaV, PetrinaM, NicotraGS, IndelicatoM, NavolanicPM, PennisiG, MazzarinoMC. (2005) Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med10, 1–6.
104.
DerosaG, D’AngeloA, TinelliC, DevangelioE, ConsoliA, MiccoliR, PennoG, Del PratoS, PanigaS, CiceroAF. (2007) Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab33, 129–134.
105.
van der ZijlNJ, HanemaaijerR, TushuizenME, SchindhelmRK, BoeropJ, RustemeijerC, BiloHJ, VerheijenJH, DiamantM. (2010) Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy?. Clin Biochem43, 635–639.
106.
PapazafiropoulouA, PerreaD, MoyssakisI, KokkinosA, KatsilambrosN, TentolourisN. (2010) Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Complications24, 20–27.
107.
LewandowskiKC, BanachE, BienkiewiczM, LewinskiA. (2011) Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: Effects of short-term and chronic hyperglycaemia. Arch Med Sci7, 294–303.
MukherjeeA, Morales-ScheihingD, ButlerPC, SotoC. (2015) Type 2 diabetes as a protein misfolding disease. Trends Mol Med21, 439–449.
111.
KonarkowskaB, AitkenJF, KistlerJ, ZhangS, CooperGJ. (2006) The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. FEBS J273, 3614–3624.
112.
ZhangS, LiuJ, DragunowM, CooperGJ. (2003) Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a caspase cascade and JNK1. J Biol Chem278, 52810–52819.
113.
HoppenerJW, OosterwijkC, NieuwenhuisMG, PosthumaG, ThijssenJH, VroomTM, AhrenB, LipsCJ. (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model. Diabetologia42, 427–434.
114.
HullRL, WestermarkGT, WestermarkP, KahnSE. (2004) Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab89, 3629–3643.
115.
JurgensCA, ToukatlyMN, FlignerCL, UdayasankarJ, SubramanianSL, ZraikaS, Aston-MourneyK, CarrDB, WestermarkP, WestermarkGT, KahnSE, HullRL. (2011) beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol178, 2632–2640.
ChristofferssonG, VagesjoE, VandoorenJ, LidenM, MassenaS, ReinertRB, BrissovaM, PowersAC, OpdenakkerG, PhillipsonM. (2012) VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood120, 4653–4662.
123.
OlssonR, MaxhuniA, CarlssonPO. (2006) Revascularization of transplanted pancreatic islets following culture with stimulators of angiogenesis. Transplantation82, 340–347.
124.
ChristofferssonG, WaldenT, SandbergM, OpdenakkerG, CarlssonPO, PhillipsonM. (2015) Matrix metalloproteinase-9 is essential for physiological Beta cell function and islet vascularization in adult mice. Am J Pathol185, 1094–1103.
125.
WilcoxG. (2005) Insulin and insulin resistance. Clin Biochem Rev26, 19–39.
AlghamdiF, GuoM, AbdulkhalekS, CrawfordN, AmithSR, SzewczukMR. (2014) A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes. Cell Signal26, 1355–1368.
129.
SwinnenSG, HoekstraJB, DeVriesJH. (2009) Insulin therapy for type 2 diabetes. Diabetes Care32(Suppl 2), 253–259.
130.
ZhouK, PedersenHK, DawedAY, PearsonER. (2016) Pharmacogenomics in diabetes mellitus: Insights into drug action and drug discovery. Nat Rev Endocrinol12, 337–346.
131.
HansonLR, FreyWH2nd. (2008) Intral delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci9(Suppl 3), 5.
132.
ZhangH, HaoY, ManorB, NovakP, MilbergW, ZhangJ, FangJ, NovakV. (2015) Intral insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes64, 1025–1034.
133.
CraftS, BakerLD, MontineTJ, MinoshimaS, WatsonGS, ClaxtonA, ArbuckleM, CallaghanM, TsaiE, PlymateSR, GreenPS, LeverenzJ, CrossD, GertonB. (2012) Intral insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol69, 29–38.
134.
RegerMA, WatsonGS, FreyWH2nd, BakerLD, CholertonB, KeelingML, BelongiaDA, FishelMA, PlymateSR, SchellenbergGD, CherrierMM, CraftS. (2006) Effects of intral insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging27, 451–458.
135.
GiannarelliR, AragonaM, CoppelliA, Del PratoS. (2003) Reducing insulin resistance with metformin: The evidence today. Diabetes Metab29, 28–35.
136.
GuptaA, BishtB, DeyCS. (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology60, 910–920.
137.
LandrethG, JiangQ, MandrekarS, HenekaM. (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics5, 481–489.
138.
GrossB, StaelsB. (2007) PPAR agonists: Multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab21, 687–710.
139.
MeierJJ. (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol8, 728–742.
140.
DuringMJ, CaoL, ZuzgaDS, FrancisJS, FitzsimonsHL, JiaoX, BlandRJ, KlugmannM, BanksWA, DruckerDJ, HaileCN. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med9, 1173–1179.
141.
LiY, DuffyKB, OttingerMA, RayB, BaileyJA, HollowayHW, TweedieD, PerryT, MattsonMP, KapogiannisD, SambamurtiK, LahiriDK, GreigNH. (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis19, 1205–1219.
142.
MackenzieRW, ElliottBT. (2014) Akt/PKB activation and insulin signaling: A novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes7, 55–64.
143.
MorrisDL, ChoKW, ZhouY, RuiL. (2009) SH2B1 enhances insulin sensitivity by both stimulating the insulin receptor and inhibiting tyrosine dephosphorylation of insulin receptor substrate proteins. Diabetes58, 2039–2047.
144.
MatusiakN, van WaardeA, BischoffR, OltenfreiterR, van de WieleC, DierckxRA, ElsingaPH. (2013) Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr Pharm Des19, 4647–4672.
145.
AlamMI, BegS, SamadA, BabootaS, KohliK, AliJ, AhujaA, AkbarM. (2010) Strategy for effective brain drug delivery. Eur J Pharm Sci40, 385–403.
146.
MalitoE, HulseRE, TangWJ. (2008) Amyloid beta-degrading cryptidases: Insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci65, 2574–2585.
SpencerB, MarrRA, GindiR, PotkarR, MichaelS, AdameA, RockensteinE, VermaIM, MasliahE. (2011) Peripheral delivery of a CNS targeted, metalo-protease reduces abeta toxicity in a mouse model of Alzheimer’s disease. PLoS One6, 16575.
150.
SpencerB, MarrRA, RockensteinE, CrewsL, AdameA, PotkarR, PatrickC, GageFH, VermaIM, MasliahE. (2008) Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behoral improvement in APP transgenic mice. BMC Neurosci9, 109.
151.
HemmingML, PattersonM, Reske-NielsenC, LinL, IsacsonO, SelkoeDJ. (2007) Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: A novel therapeutic approach to Alzheimer disease. PLoS Med4, 262.
152.
BarbashS, HaninG, SoreqH. (2013) Stereotactic injection of microRNA-expressing lentiviruses to the mouse hippocampus ca1 region and assessment of the behoral outcome. J Vis Exp, e50170.
153.
IwataN, SekiguchiM, HattoriY, TakahashiA, AsaiM, JiB, HiguchiM, StaufenbielM, MuramatsuS, SaidoTC. (2013) Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep3, 1472.
154.
TongHI, KangW, DavyPM, ShiY, SunS, AllsoppRC, LuY. (2016) Monocyte trafficking, engraftment, and delivery of nanoparticles and an exogenous gene into the acutely inflamed brain tissue - evaluations on monocyte-based delivery system for the central nervous system. PLoS One11, 0154022.
155.
TongHI, KangW, ZhouG, LiuM, ShiY, LuY. (2017) Evaluation on monocyte-mediated delivery of a therapeutic gene into the inflamed brain. Curr Gene Ther16, 401–409.
156.
WuS, SasakiA, YoshimotoR, KawaharaY, ManabeT, KataokaK, AsashimaM, YugeL. (2008) Neural stem cells improve learning and memory in rats with Alzheimer’s disease. Pathobiology75, 186–194.
157.
Blurton-JonesM, KitazawaM, Martinez-CoriaH, CastelloNA, MullerFJ, LoringJF, YamasakiTR, PoonWW, GreenKN, LaFerlaFM. (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A106, 13594–13599.
158.
ZhangW, WangPJ, ShaHY, NiJ, LiMH, GuGJ. (2014) Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer’s disease. Mol Neurobiol50, 423–437.
159.
Blurton-JonesM, SpencerB, MichaelS, CastelloNA, AgazaryanAA, DavisJL, MullerFJ, LoringJF, MasliahE, LaFerlaFM. (2014) Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther5, 46.
160.
WolfDA, HansonLR, AronovichEL, NanZ, LowWC, FreyWH, 2nd, McIvorRS. (2012) Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intral administration. Mol Genet Metab106, 131–134.
161.
ZaidiSH, YouXM, CiuraS, HusainM, RabinovitchM. (2002) Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation105, 516–521.
162.
Ramos-DeSimoneN, Hahn-DantonaE, SipleyJ, NagaseH, FrenchDL, QuigleyJP. (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem274, 13066–13076.
163.
HuK, YangJ, TanakaS, GoniasSL, MarsWM, LiuY. (2006) Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem281, 2120–2127.
164.
YabluchanskiyA, MaY, IyerRP, HallME, LindseyML. (2013) Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda)28, 391–403.
165.
BenjaminMM, KhalilRA. (2012) Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS103, 209–279.
166.
KuzniewskaB, RejmakE, MalikAR, JaworskiJ, KaczmarekL, KalitaK. (2013) Brain-derived neurotrophic factor induces matrix metalloproteinase 9 expression in neurons via the serum response factor/c-Fos pathway. Mol Cell Biol33, 2149–2162.
